Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominic T Moore

Showing results (91-100 of 105) with videos related to

Pageof 11
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 1, 2011
A randomized phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age ≥70 years) with stage IIIB/IV non-small cell lung cancerThomas E Stinchcombe, Amy H Peterman, Carrie B Lee, et al.
American Journal of Surgery|May 25, 2006
Axillary lymph node count is lower after neoadjuvant chemotherapyHeather Neuman, Lisa A Carey, David W Ollila, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2010
Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinomaC Lance Cowey, Chirag Amin, Raj S Pruthi, et al.
The Journal of Investigative Dermatology|June 29, 2007
Defective cell cycle checkpoint functions in melanoma are associated with altered patterns of gene expressionWilliam K Kaufmann, Kathleen R Nevis, Pingping Qu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2012
Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elementsD Neil Hayes, Amy S Lucas, Tawee Tanvetyanon, et al.
International Journal of Cancer|August 21, 2023
A prospective cohort study identifies two types of HIV+ Kaposi Sarcoma lesions: proliferative and inflammatoryRazia Moorad, Edwards Kasonkanji, Joe Gumulira, et al.
Journal of Experimental & Clinical Cancer Research : CR|February 9, 2021
Targeting dopamine receptor D2 as a novel therapeutic strategy in endometrial cancerStuart R Pierce, Ziwei Fang, Yajie Yin, et al.
Molecular Cancer Therapeutics|August 5, 2020
Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving RegorafenibYingmiao Liu, Jing Lyu, Kirsten Bell Burdett, et al.
JCI Insight|November 19, 2020
Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinomaChristopher G Wood, James E Ferguson, Joel S Parker, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 19, 2023
Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast TumorsBenjamin G Vincent, Danielle M File, Karen P McKinnon, et al.
Pageof 11

Showing results (91-100 of 105) with videos related to

Sort By:
Pageof 11
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 1, 2011
A randomized phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age ≥70 years) with stage IIIB/IV non-small cell lung cancerThomas E Stinchcombe, Amy H Peterman, Carrie B Lee, et al.
American Journal of Surgery|May 25, 2006
Axillary lymph node count is lower after neoadjuvant chemotherapyHeather Neuman, Lisa A Carey, David W Ollila, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2010
Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinomaC Lance Cowey, Chirag Amin, Raj S Pruthi, et al.
The Journal of Investigative Dermatology|June 29, 2007
Defective cell cycle checkpoint functions in melanoma are associated with altered patterns of gene expressionWilliam K Kaufmann, Kathleen R Nevis, Pingping Qu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2012
Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elementsD Neil Hayes, Amy S Lucas, Tawee Tanvetyanon, et al.
International Journal of Cancer|August 21, 2023
A prospective cohort study identifies two types of HIV+ Kaposi Sarcoma lesions: proliferative and inflammatoryRazia Moorad, Edwards Kasonkanji, Joe Gumulira, et al.
Journal of Experimental & Clinical Cancer Research : CR|February 9, 2021
Targeting dopamine receptor D2 as a novel therapeutic strategy in endometrial cancerStuart R Pierce, Ziwei Fang, Yajie Yin, et al.
Molecular Cancer Therapeutics|August 5, 2020
Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving RegorafenibYingmiao Liu, Jing Lyu, Kirsten Bell Burdett, et al.
JCI Insight|November 19, 2020
Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinomaChristopher G Wood, James E Ferguson, Joel S Parker, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 19, 2023
Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast TumorsBenjamin G Vincent, Danielle M File, Karen P McKinnon, et al.
Pageof 11